Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Non-hospitalised patients of both sexes aged 18 years or more with essential hypertension requiring treatment according to the recommendations of the German League for Hypertension

Exclusion criteria

Patients who had the contraindications listed in the product information (the case report file contained a copy of the product information)

Treatment and study plan

Motens® (lacidipine)

Drug

Primary outcomes

Assessment of efficacy by the investigator on a 4-point verbal rating scale based on changes in blood pressure

Time frame: Up to 12 weeks after start of drug administration
Assessment of tolerability by investigator on a 4-point verbal rating scale

Time frame: Up to 12 weeks after start of drug administration
Number of patients with adverse events

Time frame: Up to 12 weeks after start of drug administration

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension, Under Normal Conditions Compared With an Open Clinical Trial

Important dates

Study start: 1998
Primary completion: 1999
First posted: Sep 10, 2014
Registry last updated: Sep 10, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed